Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020

Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020. End Quote

(1888PressRelease) January 26, 2012 - A study undertaken by IMARC Group entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" reveals that biosimilar Insulin products in the US will grow at a CAGR of 74% during 2013-2020. Findings from the study suggest that currently three Insulin brands are expected to face biosimilar competition during 2013-2020. Eli Lilly's Humalog (Insulin Lispro) is expected to be the first drug to face biosimilar competition in 2013. Humalog is expected to be followed by Sanofi's Lantus (Insulin Glargine) and Novo Nordisk's Levemir (Insulin Detemir). The report has done a comprehensive long range forecast for each of the three products and expects Lantus to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.

IMARC's new report entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:
• Identification of currently marketed biosimilars and their historical performance
• Identifying the reasons for the slow uptake of currently marketed biosimilars
• Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
• Analyzing historical time series data on price, volume and sales erosion in the US & Europe
• Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
• Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
• Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:
• Historical background and overview
• Historical brand sales
• Patent position
• Competing products
• Biosimilars in pipeline
• Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
• Historical brand sales
• Brand and biosimilar sales forecasts
• Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:
• Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
• Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:
• An insight into the Biologics Price Competition and Innovation Act
• An insight into the key biosimilar issues that still remain unaddressed
• Interchangeability and Substitutability
• Data Exclusivity
Statutory provisions for dealing with patent litigations

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia
Email: apac ( @ ) imarcgroup dot com
Phone: +91-120-425-6531

IMARC Group North America
Email: america ( @ ) imarcgroup dot com
Phone: +1-631-791-1145

To know more please visit: http://www.imarcgroup.com/

###

space

Other Related Press Releases

Haag-Streit UK appoints a National Sales Manager to drive the business forward for 2012 by Haag-streit Uk
Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020 by Imarc Group